Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citationThe Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774 · cited 4×
“Because the AUC/MIC has been found to correlate with efficacy in experiments conducted with in vitro or animal models, this evidence has led some clinicians to question the relevance of monitoring peak serum vancomycin concentrations.(6) Consequently, some clinicians have decreased the extent of pharmacokinetic monito…”
BackgroundMethodResultInfluentialSelf-citationSoriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J. (2008) · Clinical Infectious Diseases · doi:10.1086/524667 · Cited by 767 · cited 1×
“Soriano et al.(59) evaluated the influence of vancomycin MIC on outcome in a total of 414 episodes of MRSA bacteremic patients.”
BackgroundMandell, Douglas, and Bennett's principles and practice of infectious diseases
Gillespie, S. H. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70159-6 · Cited by 705
Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Self-citationCraig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Self-citationLodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M., & Stellrecht, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-08 · Cited by 553
Self-citationHowden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484 · cited 2×
“In addition, studies have suggested that trough serum vancomycin concentrations of <10 mg/L may predict therapeutic failure and the potential for the emergence of VISA or VRSA.(54,55) Studies of MRSA and hVISA bacteremia have revealed significantly higher rates of morbidity in patients infected with hVISA.”
BackgroundThe Periodic Health Examination
(1934) · New England Journal of Medicine · doi:10.1056/nejm193401252100413 · Cited by 483
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452 · cited 2×
“aureus MIC was ≥4 mg/L.(51) Despite the change in susceptibility and resistance breakpoints, two reports have suggested that patients with S.”
BackgroundSelf-citationRetrospective study of the toxicity of preparations of vancomycin from 1974 to 1981
Farber, B. F., & Moellering, R. C. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.1.138 · Cited by 432
Self-citationRybak, M. J., Abate, B. J., Kang, S. L., Ruffing, M. J., Lerner, S. A., & Drusano, G. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1549 · Cited by 431 · cited 1×
“In humans, nephrotoxicity due to vancomycin monotherapy with typical dosage regimens is uncommon, is usually reversible, and occurs with an incidence only slightly above what is reported with other antimicrobials not considered to be nephrotoxic.(11,83,93-96) Investigators have administered a wide dosing range of vanc…”
BackgroundSelf-citationSteinkraus, G., White, R., & Friedrich, L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm258 · Cited by 420
Nephrotoxicity of vancomycin, alone and with an aminoglycoside
Rybak, M. J., Albrecht, L. M., Boike, S. C., & Chandrasekar, P. H. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.4.679 · Cited by 388 · cited 4×
“Rybak et al.(10) found that patients given vancomycin and an aminoglycoside were 6.”
BackgroundInfluentialSelf-citationWysocki, M., Delatour, F., Faurisson, F., Rauss, A., Pean, Y., Misset, B., Thomas, F., Timsit, J.-F., Similowski, T., Mentec, H., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2460-2467.2001 · Cited by 385 · cited 1×
“Further, in a randomized study, Wysocki et al.(37,38) evaluated 160 patients with severe staphylococcal infections.”
BackgroundCharles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P., & Grayson, M. L. (2004) · Clinical Infectious Diseases · doi:10.1086/381093 · Cited by 384
Pharmacokinetics of vancomycin in patients with various degrees of renal function
Matzke, G. R., McGory, R. W., Halstenson, C. E., & Keane, W. F. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.4.433 · Cited by 362
Wang, G., Hindler, J. F., Ward, K. W., & Bruckner, D. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01388-06 · Cited by 358 · cited 1×
“While this approach is not currently supported by evidence from large randomized clinical trials, vancomycin loading doses can be considered in the treatment of serious MRSA infections.(63,74)”
BackgroundJeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334 · cited 1×
“Jeffres et al.(87) conducted a similar but prospective investigation of 94 patients with health-care-associated pneumonia.”
BackgroundMoise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A., & Moellering, R. C. (2004) · Clinical Infectious Diseases · doi:10.1086/421092 · Cited by 332 · cited 3×
“Also rare is reversible ototoxicity such as tinnitus, which can occur with or without high-tone deafness.(33,120,127) Investigation of pediatric pneumococcal meningitis noted that early vancomycin administration (relative to ceftriaxone administration) was associated with a substantially increased risk of hearing loss…”
BackgroundMethodSelf-citationLiu, C., & Chambers, H. F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3040-3045.2003 · Cited by 321
Martindale: The Extra Pharmacopoeia.
(1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-1-144_1 · Cited by 316
Lamer, C., de Beco, V, Soler, P., Calvat, S., Fagon, J. Y., Dombret, M. C., Farinotti, R., Chastre, J., & Gibert, C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.281 · Cited by 297 · cited 1×
“Epithelial lining fluid (ELF) penetration in critically injured patients is highly variable, with an overall blood:ELF penetration ratio of 6:1.(23,24)”
BackgroundLaPlante, K. L., & Rybak, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4665-4672.2004 · Cited by 284
Self-citationVancomycin: A 50-Year Reassessment
Moellering, R. C. (2006) · Clinical Infectious Diseases · doi:10.1086/491708 · Cited by 275 · cited 1×
“aureus (MRSA).(1) Early use of vancomycin was associated with a number of adverse effects, including infusionrelated toxicities, nephrotoxicity, and possible ototoxicity.”
BackgroundSelf-citationPenetration of vancomycin into human lung tissue
Cruciani, M., Gatti, G., Lazzarini, L., Furlan, G., Broccali, G., Malena, M., Franchini, C., & Concia, E. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.5.865 · Cited by 264 · cited 1×
“Vancomycin concentrations in lung tissue ranging from 5% to 41% of serum vancomycin concentrations have been reported in studies of healthy volunteers and patients.(5,6,22,23) Epithelial lining fluid (ELF) penetration in critically injured patients is highly variable, with an overall blood:ELF penetration ratio of 6:1.”
BackgroundPai, M. P., & Bearden, D. T. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1081 · Cited by 256
Jones, R. N. (2006) · Clinical Infectious Diseases · doi:10.1086/491710 · Cited by 254 · cited 1×
“aureus strains by Jones(57) found that the MIC required to inhibit the growth of 50% of organisms or the MIC required to inhibit the growth of 90% of organisms (MIC 90 ) for vancomycin is 1 mg/L.(57) The Centers for Disease Control and Prevention 2005 U.”
BackgroundVancomycin pharmacokinetics in patients with various degrees of renal function
Rodvold, K. A., Blum, R. A., Fischer, J. H., Zokufa, H. Z., Rotschafer, J. C., Crossley, K. B., & Riff, L. J. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.6.848 · Cited by 249
Self-citationEuropean Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group, & National Cancer Institute of Canada-Clinical Trials Group (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.5.951 · Cited by 246
Vancomycin pharmacokinetics in normal and morbidly obese subjects
Blouin, R. A., Bauer, L. A., Miller, D. D., Record, K. E., & Griffen, W. O. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.4.575 · Cited by 233 · cited 1×
“There are limited data on dosing in obese patients; however, initial dosages should be based on ABW and adjusted based on serum vancomycin concentrations to achieve therapeutic levels.(17) Vancomycin is ideally suited from a pharmacokinetic and pharmacodynamic perspective for intermittent administration based on the u…”
Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value
Cantu, T. G., Yamanaka-Yuen, N. A., & Lietman, P. S. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.533 · Cited by 230 · cited 3×
“However, these markers are very sensitive and could reflect transient hypotension due to rapid administration rather than toxicity.(8) Enzymuria in humans was minimally affected during five days of vancomycin therapy.”
BackgroundInfluentialMoise, P. A., Sakoulas, G., Forrest, A., & Schentag, J. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00939-06 · Cited by 225 · cited 1×
“In a more recent study of patients with MRSA bacteremia (n = 34), Moise et al.(58) demonstrated that patients with”
BackgroundHowden, B. P., Johnson, P. D. R., Ward, P. B., Stinear, T. P., & Davies, J. K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00422-06 · Cited by 224 · cited 1×
“Studies of MRSA and hVISA bacteremia have revealed significantly higher rates of morbidity in patients infected with hVISA.(50,55,56) These patients were more likely to have high bacterial load infections, low initial trough serum vancomycin concentrations, and treatment failure.”
BackgroundStaphylococcus aureus with Reduced Susceptibility to Vancomycin
Cosgrove, S. E., Carroll, K. C., & Perl, T. M. (2004) · Clinical Infectious Diseases · doi:10.1086/422458 · Cited by 223 · cited 1×
“) Although infection with these organisms is infrequent, there is fear that the organisms could become more prevalent if the high rate of use and exposure pressure of vancomycin continues.(47) The discovery of inducible hVISA (i.”
Jeffres, M. N., Isakow, W., Doherty, J. A., McKinnon, P. S., Ritchie, D. J., Micek, S. T., & Kollef, M. H. (2006) · Chest · doi:10.1378/chest.130.4.947 · Cited by 219
Bertino, J. S., Booker, L. A., Franck, P. A., Jenkins, P. L., Franck, K. R., & Nafziger, A. N. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.1.173 · Cited by 197 · cited 1×
“Bertino et al.(107) found vancomycin to be an independent risk factor for aminoglycoside nephrotoxicity in a review of 1489 patients who prospectively received individualized pharmacokinetic monitoring.”
BackgroundSakoulas, G., Eliopoulos, G. M., Moellering, Jr., Novick, R. P., Venkataraman, L., Wennersten, C., DeGirolami, P. C., Schwaber, M. J., & Gold, H. S. (2003) · The Journal of Infectious Diseases · doi:10.1086/368128 · Cited by 187 · cited 3×
“Sakoulas et al.(67,68) have determined in in vitro studies that the emergence of hVISA or VISA may occur when S.”
BackgroundSelf-citationKarp, J. E., Dick, J. D., Angelopulos, C., Charache, P., Green, L., Burke, P. J., & Saral, R. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90257-3 · Cited by 186
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations
Rotschafer, J. C., Crossley, K., Zaske, D. E., Mead, K., Sawchuk, R. J., & Solem, L. D. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.22.3.391 · Cited by 185
Self-citationMohr, J. F., & Murray, B. E. (2007) · Clinical Infectious Diseases · doi:10.1086/518451 · Cited by 185
The Periodic Health Examination: 1980
DELBANCO, T. L., & TAYLOR, W. C. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-2-251 · Cited by 179
A prospective study of adverse reactions associated with vancomycin therapy
Sorrell, T. C., & Collignon, P. J. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/16.2.235 · Cited by 175 · cited 4×
“Data regarding concurrent vancomycin and aminoglycoside administration in humans provide conflicting information, with some reports indicating that the combination augments aminoglycoside-induced nephrotoxicity,(11,76,81,83,91,94,106,107) and others indicating no effect.(81,83,85,86,96,108-111) Rybak et al.”
BackgroundInfluentialCounterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence
Deresinski, S. (2007) · Clinical Infectious Diseases · doi:10.1086/518452 · Cited by 173 · cited 1×
“evaluated the relationship between vancomycin MIC of 2 mg/L, have raised the question of whether the breakpoint for vancomycin resistance should be lowered even further.(65) New information is emerging regarding the importance of the accessory gene regulator (agr), a global quorum-sensing regulator in S.”
BackgroundThe Role of Vancomycin in the Treatment Paradigm
Stevens, D. L. (2006) · Clinical Infectious Diseases · doi:10.1086/491714 · Cited by 172 · cited 1×
“Vancomycin concentrations in lung tissue ranging from 5% to 41% of serum vancomycin concentrations have been reported in studies of healthy volunteers and patients.(5,6,22,23) Epithelial lining fluid (ELF) penetration in critically injured patients is highly variable, with an overall blood:ELF penetration ratio of 6:1.”
BackgroundPharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients
del Mar Fernández de Gatta Garcia, M., Revilla, N., Calvo, M. V., Domínguez-Gil, A., & Sánchez Navarro, A. (2007) · Intensive Care Medicine · doi:10.1007/s00134-006-0470-5 · Cited by 169 · cited 1×
“aureus MIC values, del Mar Fernández de Gatta Garcia et al.(71) reported that a daily dosage of 3–4 g of vancomycin would be required to provide 90% probability of attaining a target AUC/MIC of 400 with an MIC of 1 mg/L.”
BackgroundIngram, P. R., Lye, D. C., Tambyah, P. A., Goh, W. P., Tam, V. H., & Fisher, D. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn080 · Cited by 163
Sakoulas, G., Eliopoulos, G. M., Fowler, V. G., Moellering, R. C., Novick, R. P., Lucindo, N., Yeaman, M. R., & Bayer, A. S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2687-2692.2005 · Cited by 162 · cited 1×
“Sakoulas et al.(67,68) have determined in in vitro studies that the emergence of hVISA or VISA may occur when S.”
BackgroundSelf-citationThomson, A. H., Staatz, C. E., Tobin, C. M., Gall, M., & Lovering, A. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp085 · Cited by 151
Vancomycin Ototoxicity and Nephrotoxicity
Bailie, G. R., & Neal, D. (1988) · Medical Toxicology · doi:10.1007/bf03259891 · Cited by 150
Moore, M. R., Perdreau‐Remington, F., & Chambers, H. F. “. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1262-1266.2003 · Cited by 149
Sakoulas, G., Gold, H. S., Cohen, R. A., Venkataraman, L., Moellering, R. C., & Eliopoulos, G. M. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl030 · Cited by 149
Self-citationMartindale: The extra pharmacopoeia
Goldman, K. P. (1983) · Tubercle · doi:10.1016/0041-3879(83)90041-7 · Cited by 146
Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination
Goetz, M. B., & Sayers, J. F. B. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.2.325 · Cited by 145
James, J. K., Palmer, S. M., Levine, D. P., & Rybak, M. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.696 · Cited by 143 · cited 1×
“Using a randomized crossover study design in intensive care unit (ICU) patients, James et al.(35) found no significant difference between intermittent and continuous administrations when measuring killing activity in vitro, although the ability to maintain serum bactericidal titers above 1:8 was better with a continuo…”
MethodSelf-citationPneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides*
Rello, J., Solé‐Violán, J., Borges-Sa, M., Garnacho‐Montero, J., Muñoz, E., Sirgo, G., Olona, M., & Dı́az, E. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000178180.61305.1d · Cited by 141
Lamp, K. C., Rybak, M. J., Bailey, E. M., & Kaatz, G. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2709 · Cited by 131
Self-citationCimino, M. A., Rotstein, C., Slaughter, R. L., & Emrich, L. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90947-8 · Cited by 128
Löwdin, E., Odenholt, I., & Cars, O. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2739 · Cited by 126
Editorial: Monitoring Serum Vancomycin Levels: Climbing the Mountain Because It Is There?
Moellering, R. C. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.4.544 · Cited by 123
Self-citationZimmermann, A. E., Katona, B. G., & Plaisance, K. I. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04335.x · Cited by 123 · cited 1×
“Zimmermann et al.(114) found no correlation between nephrotoxicity and initial serum creatinine concentration, length of hospital stay, or duration of vancomycin therapy.”
BackgroundVancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects
Golper, T. A., Noonan, H. M., Elzinga, L. W., Gilbert, D. N., Brummett, R. E., Anderson, J. L., & Bennett, W. M. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.74 · Cited by 121
Pharmacodynamics: Relation to Antimicrobial Resistance
Rybak, M. J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.04.001 · Cited by 120
Self-citationVancomycin- and erythromycin-induced hearing loss in humans
Brummett, R. E., & Fox, K. E. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.6.791 · Cited by 119
Ackerman, B. H., Vannier, A. M., & Eudy, E. B. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.8.1766 · Cited by 118
Impaired Target Site Penetration of Vancomycin in Diabetic Patients following Cardiac Surgery
Skhirtladze, K., Hutschala, D., Fleck, T., Thalhammer, F., Ehrlich, M. P., Vukovich, T., Müller, M., & Tschernko, E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1372-1375.2006 · Cited by 116 · cited 2×
“94 mg/L).(21) Vancomycin concentrations in lung tissue ranging from 5% to 41% of serum vancomycin concentrations have been reported in studies of healthy volunteers and patients.”
BackgroundVancomycin toxicity: a prospective study
Mellor, J., Kingdom, J. C., CAFFERKEY, M. T., & Keane, C. T. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/15.6.773 · Cited by 110
Elting, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V. I., Fangtang, J. T., Martin, C. G., RAAD, I. I., Whimbey, E. E., Manzullo, E. F., & Bodey, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2597::aid-cncr27>3.0.co;2-l · Cited by 109
Clinical Efficacy of Therapeutic Drug Monitoring in Patients Receiving Vancomycin
Iwamoto, T., Kagawa, Y., & Kojima, M. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.876 · Cited by 108 · cited 1×
“Other factors associated with decreased toxicity include shorter courses of therapy, less total dosage in grams of the drug, and a decreased length of hospital stay.(7,12,116,117) However, Darko et al.”
BackgroundTsuji, B. T., Rybak, M. J., Cheung, C. M., Amjad, M., & Kaatz, G. W. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.10.021 · Cited by 105 · cited 1×
“Subsequently, the investigators determined that as many as 48% of hospital-associated MRSA had a dysfunctional agr locus, making this finding potentially clinically relevant and warranting further evaluation.(70)”
BackgroundSelf-citationLarsson, A. J., Walker, K. J., Raddatz, J. K., & Rotschafer, J. C. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.4.589 · Cited by 105 · cited 2×
“By simulating free vancomycin peak concentrations of 40, 20, 10, and 5 mg/L in an in vitro chemostat model with a normal vancomycin terminal half-life of six hours, Larsson et al.(31) found no difference in the corresponding bacterial kill curves for S.”
BackgroundSelf-citationMild Nephrotoxicity Associated With Vancomycin Use
Downs, N. J. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390080053013 · Cited by 102 · cited 2×
“Data regarding concurrent vancomycin and aminoglycoside administration in humans provide conflicting information, with some reports indicating that the combination augments aminoglycoside-induced nephrotoxicity,(11,76,81,83,91,94,106,107) and others indicating no effect.(81,83,85,86,96,108-111) Rybak et al.”
BackgroundVancomycin Ototoxicity in a Patient with Normal Renal Function
Traber, P. G., & Levine, D. P. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-95-4-458 · Cited by 99 · cited 2×
“Also rare is reversible ototoxicity such as tinnitus, which can occur with or without high-tone deafness.(33,120,127) Investigation of pediatric pneumococcal meningitis noted that early vancomycin administration (relative to ceftriaxone administration) was associated with a substantially increased risk of hearing loss…”
BackgroundSelf-citationKing, D. W., & Smith, M. A. (2004) · Toxicology in Vitro · doi:10.1016/j.tiv.2004.03.013 · Cited by 97 · cited 2×
“The filtration and energy-dependent transport mechanisms found in the proximal tubular epithelium render the kidneys susceptible to toxicant-induced injury.(89) Vancomycin exposure in renal proximal tubule epithelial cells results in increased cell proliferation.”
BackgroundImpact of Vancomycin Therapeutic Drug Monitoring on Patient Care
Welty, T. E., & Copa, A. K. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402801201 · Cited by 93 · cited 1×
“Other factors associated with decreased toxicity include shorter courses of therapy, less total dosage in grams of the drug, and a decreased length of hospital stay.(7,12,116,117) However, Darko et al.”
BackgroundProtective Effects of Different Antioxidants and Amrinone on Vancomycin‐Induced Nephrotoxicity
Çelik, İ., Cihangiroğlu, M., İlhan, N., Akpolat, N., & Akbulut, H. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_153.x · Cited by 92 · cited 1×
“In rats, antioxidants protect kidneys against vancomycininduced injury, in theory, by inhibiting free oxygen radical production.(90) Human data suggest toxicity from vancomycin (or aminoglycosides) is not confined to the proximal tubule but may also involve the medullary region (loop of Henle and collecting duct) of t…”
BackgroundWhy monitor peak vancomycin concentrations?
Saunders, N. J. S. G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92890-8 · Cited by 92
Tsuji, B. T., Rybak, M. J., Lau, K. L., & Sakoulas, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00671-06 · Cited by 90 · cited 1×
“Tsuji et al.(69) used an in vitro pharmacodynamic model to evaluate S.”
MethodSelf-citationVancomycin enhancement of experimental tobramycin nephrotoxicity
Wood, C. A., Kohlhepp, S. J., Kohnen, P. W., Houghton, D. C., & Gilbert, D. N. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.1.20 · Cited by 86 · cited 2×
“Vancomycin has not been found to be ototoxic in animal models.(97,98,100,118,119) Early literature attributed ototoxic events to impurities or to concurrent ototoxic agents.”
BackgroundDarko, W., Medicis, J. J., Smith, A., Guharoy, R., & Lehmann, D. F. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.643.32199 · Cited by 81
Treatment of Staphylococcal Septicemia with Vancomycin
Kirby, W. M. M., Perry, D. M., & Bauer, A. W. (1960) · New England Journal of Medicine · doi:10.1056/nejm196001142620201 · Cited by 81
Wilhelm, M. P., & Estes, L. L. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.9.928 · Cited by 78
Je, G., Heilman, F. R., Nichols, D. R., & WELLMAN, W. E. (1958) · PubMed · Cited by 77
Toxicology of Vancomycin in Laboratory Animals
Wold, J. S., & Turnipseed, S. A. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.supplement_2.s224 · Cited by 77
Outcome Assessment of Minimizing Vancomycin Monitoring and Dosing Adjustments
Karam, C. M., McKinnon, P. S., Neuhauser, M. M., & Rybak, M. J. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.4.257.30933 · Cited by 75
Self-citationPulmonary disposition of vancomycin in critically ill patients
Georges, H., Leroy, O., Alfandari, S., Guery, B. P., Roussel‐Delvallez, M., Dhennain, C., & Beaucaire, G. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726369 · Cited by 74 · cited 2×
“Epithelial lining fluid (ELF) penetration in critically injured patients is highly variable, with an overall blood:ELF penetration ratio of 6:1.(23,24)”
BackgroundNecessity of a loading dose when using vancomycin in critically ill patients
Wang, J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.2.246 · Cited by 71 · cited 1×
“aureus infections, a vancomycin loading dose of 25 mg/kg infused at a rate of 500 mg/hr was found to be safe without producing toxic peak serum drug levels.(73) While this approach is not currently supported by evidence from large randomized clinical trials, vancomycin loading doses can be considered in the treatment…”
BackgroundRisk of Nephrotoxicity with Combination Vancomycin‐Aminoglycoside Antibiotic Therapy
Pauly, D. J., Musa, D. M., Lestico, M. R., Lindstrom, M. J., & Hetsko, C. M. (1990) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1990.tb03566.x · Cited by 65 · cited 3×
“Data regarding concurrent vancomycin and aminoglycoside administration in humans provide conflicting information, with some reports indicating that the combination augments aminoglycoside-induced nephrotoxicity,(11,76,81,83,91,94,106,107) and others indicating no effect.(81,83,85,86,96,108-111) Rybak et al.”
BackgroundNishino, Y., Takemura, S., Minamiyama, Y., Hirohashi, K., Tanaka, H., Inoue, M., Okada, S., & Kinoshita, H. (2002) · Redox Report · doi:10.1179/135100002125000884 · Cited by 59 · cited 1×
“Vancomycin destruction of glomeruli and necrosis of the proximal tubule are thought to be due to oxidative stress.(92) In humans, nephrotoxicity due to vancomycin monotherapy with typical dosage regimens is uncommon, is usually reversible, and occurs with an incidence only slightly above what is reported with other an…”
BackgroundPeetermans, W. E., Hoogeterp, J. J., Dokkum, A. M. H.-V., van den Broek, P., & Mattie, H. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.10.1869 · Cited by 58
Cohen, E., Dadashev, A., Drucker, M., Samra, Z., Rubinstein, E., & Garty, M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.155 · Cited by 58 · cited 1×
“71).(112) However, “high-dose” (defined as a total daily dose of 40 mg/kg, either as a continuous infusion or divided every 12 hours, resulting in a mean ± S.”
BackgroundVancomycin Serum Protein Binding Determination by Ultrafiltration
Ackerman, B. H., Taylor, E. H., Olsen, K. M., Abdel-Malak, W., & Pappas, A. A. (1988) · Annals of Pharmacotherapy · doi:10.1177/106002808802200404 · Cited by 58 · cited 1×
“While reports of the degree of vancomycin protein binding have varied, a level of 50–55% is most often stated.(19,20) Penetration of vancomycin into tissues is variable and can be affected by inflammation and disease state.”
BackgroundWysocki, M., THOMAS, F., Wolff, M., Pean, Y., Ravaud, Y., & HERMAN, B. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/35.2.352 · Cited by 57 · cited 1×
“Further, in a randomized study, Wysocki et al.(37,38) evaluated 160 patients with severe staphylococcal infections.”
BackgroundRenal tolerance and pharmacokinetics of vancomycin in rats
Marre, R., Schulz, E., Anders, T., & Sack, K. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.3.253 · Cited by 56
Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats
Beauchamp, D., Pellerin, M., Gourde, P., Pettigrew, M., & Bergeron, M. G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.139 · Cited by 55
Nahata, M. C. (2009) · Chemotherapy · doi:10.1159/000238512 · Cited by 49
Murphy, J. E., Gillespie, D. E., & Bateman, C. V. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060047 · Cited by 49 · cited 1×
“The use of a nomogram is an alternative method for dosage adjustments; however, the majority of published nomograms in clinical use have been proven to be inaccurate, and most have not been clinically validated.(72) In addition, no published nomogram to date has been constructed to achieve trough serum vancomycin conc…”
MethodEffects of vancomycin on renal function in rats
Aronoff, G. R., Sloan, R. S., Dinwiddie, C. B., Glant, M. D., Fineberg, N. S., & Luft, F. C. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.19.2.306 · Cited by 48 · cited 3×
“Investigators have administered a wide dosing range of vancomycin monotherapy to rats without appreciable renal injury.(97,98) Renal impairment in rats was observed when concurrent aminoglycosides were administered(97-99) or if very high dosages of vancomycin were used (350 mg/kg twice daily for four days).”
BackgroundMoyec, L. L., Racine, S. X., Toumelin, P. L., Adnet, F., Larue, V., Cohen, Y., Leroux, Y., Cupa, M., & Hantz, E. (2002) · Critical Care Medicine · doi:10.1097/00003246-200206000-00013 · Cited by 44 · cited 1×
“Human data suggest toxicity from vancomycin (or aminoglycosides) is not confined to the proximal tubule but may also involve the medullary region (loop of Henle and collecting duct) of the nephron.(91) Vancomycin destruction of glomeruli and necrosis of the proximal tubule are thought to be due to oxidative stress.”
BackgroundEarly Vancomycin Therapy and Adverse Outcomes in Children With Pneumococcal Meningitis
Buckingham, S. C., McCullers, J. A., Luján‐Zilbermann, J., Knapp, K. M., Orman, K. L., & English, B. K. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2282 · Cited by 44 · cited 1×
“Investigation of pediatric pneumococcal meningitis noted that early vancomycin administration (relative to ceftriaxone administration) was associated with a substantially increased risk of hearing loss due to the effects of rapid bacterial killing by both antimicrobials and the resultant host inflammatory response.(12…”
BackgroundLoading dose of vancomycin in critically ill patients: 15mg/kg is a better choice than 500mg
Mohammédi, I., Descloux, É., Argaud, L., LESCANFF, J., & Robert, D. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.11.009 · Cited by 41 · cited 2×
“In the 1960s, purity increased to 75% and in 1985 to 92–95% for Eli Lilly’s vancomycin product.(74) Concurrently, a decrease in the reporting of serious adverse events occurred.”
BackgroundComparative Clinical Effectiveness and Toxicity of Vancomycin, Ristocetin, and Kanamycin
WAISBREN, B. A. (1960) · Archives of Internal Medicine · doi:10.1001/archinte.1960.03820020019005 · Cited by 41
Vancomycin Protein Binding in Patients with Infections Caused by Staphylococcus Aureus
Albrecht, L. M., Rybak, M. J., Warbasse, L. H., & Edwards, D. J. (1991) · DICP · doi:10.1177/106002809102500701 · Cited by 41 · cited 1×
“While reports of the degree of vancomycin protein binding have varied, a level of 50–55% is most often stated.(19,20) Penetration of vancomycin into tissues is variable and can be affected by inflammation and disease state.”
BackgroundSelf-citationRybak, M. J., & Boike, S. C. (1986) · Annals of Pharmacotherapy · doi:10.1177/106002808602001003 · Cited by 40 · cited 1×
“It is most likely to occur when larger dosages are infused too rapidly (>500 mg over ≤30 minutes).(7,77,78) Vancomycin should be administered intravenously over an infusion period of at least 1 hour to minimize infusionrelated adverse effects.”
BackgroundSelf-citationFekety, R. (1982) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31451-1 · Cited by 40
Rhee, K. Y., Gardiner, D., & Charles, M. (2005) · Clinical Infectious Diseases · doi:10.1086/430175 · Cited by 38
Vancomycin-Induced Neutropenia
Koo, K., Bachand, R. L., & CHOW, A. W. C. (1986) · Annals of Pharmacotherapy · doi:10.1177/106002808602001010 · Cited by 37
Bickel, M., Stephan, C., Rottmann, C., Carlebach, A., Haberl, A., Kurowski, M., & Staszewski, S. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410020901 · Cited by 37
Svensson, E., Hanberger, H., & Nilsson, L. E. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.107 · Cited by 33
Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children.
Mp, G., Dk, B., & Jl, S. (1989) · PubMed · Cited by 31
Vancomycin-Induced Neutropenia during Treatment of Osteomyelitis in an Outpatient
Henry, K., Steinberg, I., & Crossley, K. (1986) · Annals of Pharmacotherapy · doi:10.1177/106002808602001011 · Cited by 29 · cited 1×
“Less frequent adverse events, such as neutropenia, also appear unrelated to serum drug concentrations.(79,80) Vancomycin has long been considered a nephrotoxic and ototoxic agent.”
BackgroundChrononephrotoxicity in Rat of a Vancomycin and Gentamicin Combination
Fauconneau, B., de Lemos, E., Pariat, C., Bouquet, S., Courtois, P., & Piriou, A. (1992) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1992.tb00516.x · Cited by 27
Murray, B. E., & Nannini, E. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00031-x · Cited by 26
Influence of fosfomycin and tobramycin on vancomycin-induced nephrotoxicity
Marre, R., Schulz, E., Hedtke, D., & Sack, K. (1985) · Infection · doi:10.1007/bf01642811 · Cited by 22
Rybak, M. J., Frankowski, J. J., Edwards, D. J., & Albrecht, L. M. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.10.1461 · Cited by 22 · cited 1×
“Enzymuria in humans was minimally affected during five days of vancomycin therapy.(105) Data regarding concurrent vancomycin and aminoglycoside administration in humans provide conflicting information, with some reports indicating that the combination augments aminoglycoside-induced nephrotoxicity,(11,76,81,83,91,94,1…”
BackgroundSelf-citationAn experimental study of vancomycin-induced cochlear damage
Tange, R. A., Kieviet, H. L., van Marle, J., Bagger-Sj�b�ck, D., & Ring, W. (1989) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/bf00457456 · Cited by 20
Malacarne, P., Bergamasco, S., & Donadio, C. (2006) · Chemotherapy · doi:10.1159/000093269 · Cited by 19
Lacy, M. K., Tessier, P. R., Nicolau, D. P., Nightingale, C. H., & Quintiliani, R. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00121-7 · Cited by 16 · cited 1×
“In a similarly designed study in healthy subjects, Lacy et al.(36) found virtually no difference in activity as measured by bactericidal titers between continuous and intermittent infusions.”
BackgroundThe Ototoxic Interaction of Viomycin, Capreomycin and Polymyxin B With Ethacrynic Acid
Davis, R. R., Brummett, R. E., Bendrick, T. W., & Himes, D. L. (1982) · Acta Oto-Laryngologica · doi:10.3109/00016488209130874 · Cited by 12 · cited 1×
“Vancomycin has not been found to be ototoxic in animal models.(97,98,100,118,119) Early literature attributed ototoxic events to impurities or to concurrent ototoxic agents.”
BackgroundKacew, S., Hewitt, W. R., & Hook, J. B. (1989) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(89)90111-7 · Cited by 10
Cost-ineffectiveness of serum vancomycin levels
Cunha, B. A., Mohan, S. S., Hamid, N., McDermott, B. P., & Daniels, P. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0314-4 · Cited by 10 · cited 1×
“Data regarding concurrent vancomycin and aminoglycoside administration in humans provide conflicting information, with some reports indicating that the combination augments aminoglycoside-induced nephrotoxicity,(11,76,81,83,91,94,106,107) and others indicating no effect.(81,83,85,86,96,108-111) Rybak et al.”
BackgroundFrequency of Nephrotoxicity with Vancomycin and Aminoglycoside Antibiotic Therapy
Hailemeskel, B., Namanny, M. D., & Wutoh, A. K. (1999) · Hospital Pharmacy · doi:10.1177/194512539903401209 · Cited by 10
Prospective Assessment of Nephrotoxicity with Concomitant Aminoglycoside and Vancomycin Therapy
Salama, S. E., & Rotstein, C. (1993) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v46i2.2479 · Cited by 10 · cited 1×
“Most of the available data suggest a 3- to 4-fold increase in nephrotoxicity when aminoglycosides are combined with vancomycin.(81,83,93,94) Synergistic toxicity may also occur when vancomycin is used with other nephrotoxic agents (e.”
Background
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
“What are the recommendations for vancomycin dosing and monitoring? These recommendations are based on a consensus statement of the American Society of Health-System Pharmacists, the IDSA, and the Society of Infectious Diseases Pharmacists on guidelines for vancomycin dosing [3,4].”
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W., Steckelberg, J. M., Rao, N., Hanssen, A., & Wilson, W. R. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis803 · Cited by 2,266
“R ec en t gu id el in es [7 , 8] fo r th e tr ea tm en t of m et hi ci lli nre si st an t St ap hy lo co cc us au re us (M R S A ) in fe ct io ns ha ve be en pu bl is he d.”
Background
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.